img

Global Ischemia Reperfusion Injury Therapeutics Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 320 | Industry : Medical Care

Publisher : GRD Survey | Format : PDF

Global Ischemia Reperfusion Injury Therapeutics Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global Ischemia Reperfusion Injury Therapeutics market is estimated at million US$ in 2021 and is expected to million US$ by the end of 2028, growing at a CAGR of % in the forecast period from 2022 to 2028.

This report studies the Ischemia Reperfusion Injury Therapeutics market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Ischemia Reperfusion Injury Therapeutics in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
ANV-6L15
APP-103
BAY-606583
EP-80317
GS-459679
KN-93
LH-021
Others

Market Snapshot, By Application
Clinic
Hospital
Others

Main Market Players Analyzed in this report, including
Zealand Pharma A/S
Stealth BioTherapeutics Inc.
Prothix BV
Proteo, Inc.
Prolong Pharmaceuticals
PledPharma AB
Pharming Group N.V.
Orexo AB
Opsona Therapeutics Limited
Omeros Corporation
Nyken B.V.
Gilead Sciences, Inc.
Erimos Pharmaceuticals, LLC
Ensemble Therapeutics Corporation
Curatis Pharma GmbH
Bolder Biotechnology, Inc.
Biomedica Management Corporation
Bayer AG
Antipodean Pharmaceuticals, Inc.
Angion Biomedica Corp.
Amyndas Pharmaceuticals LLC

The study objectives of this report are
To study and analyze the global Ischemia Reperfusion Injury Therapeutics market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Ischemia Reperfusion Injury Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Ischemia Reperfusion Injury Therapeutics manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Ischemia Reperfusion Injury Therapeutics market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Ischemia Reperfusion Injury Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Ischemia Reperfusion Injury Therapeutics are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Ischemia Reperfusion Injury Therapeutics Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Ischemia Reperfusion Injury Therapeutics Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Ischemia Reperfusion Injury Therapeutics

3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Clinic
3.2.2 Major Buyers in Hospital

4 Market Segment: by Type
4.1 Ischemia Reperfusion Injury Therapeutics Type Introduction
4.1.1 ANV-6L15
4.1.2 APP-103
4.1.3 BAY-606583
4.1.4 EP-80317
4.1.5 GS-459679
4.1.6 KN-93
4.1.7 LH-021
4.1.8 Others
4.2 Global Ischemia Reperfusion Injury Therapeutics Revenue by Type 2016-2021

5 Market Segment: by Application
5.1 Ischemia Reperfusion Injury Therapeutics Type Introduction
5.1.1 Clinic
5.1.2 Hospital
5.1.3 Others
5.2 Global Ischemia Reperfusion Injury Therapeutics Revenue by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Ischemia Reperfusion Injury Therapeutics Market by Region
6.2 North America Ischemia Reperfusion Injury Therapeutics Market 2016-2021
6.3 Europe Ischemia Reperfusion Injury Therapeutics Market 2016-2021
6.4 Asia Pacific Ischemia Reperfusion Injury Therapeutics Market 2016-2021
6.5 South America Ischemia Reperfusion Injury Therapeutics Market 2016-2021
6.6 Middle East and Africa Ischemia Reperfusion Injury Therapeutics Market 2016-2021

7 North America
7.1 North America Ischemia Reperfusion Injury Therapeutics Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Ischemia Reperfusion Injury Therapeutics Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Ischemia Reperfusion Injury Therapeutics Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Ischemia Reperfusion Injury Therapeutics Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Ischemia Reperfusion Injury Therapeutics Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Zealand Pharma A/S
12.1.1 Zealand Pharma A/S Company Information
12.1.2 Zealand Pharma A/S Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.1.3 Zealand Pharma A/S Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.1.4 Zealand Pharma A/S Key Development
12.2 Stealth BioTherapeutics Inc.
12.2.1 Stealth BioTherapeutics Inc. Company Information
12.2.2 Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.2.3 Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.2.4 Stealth BioTherapeutics Inc. Key Development
12.3 Prothix BV
12.3.1 Prothix BV Company Information
12.3.2 Prothix BV Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.3.3 Prothix BV Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.3.4 Prothix BV Key Development
12.4 Proteo, Inc.
12.4.1 Proteo, Inc. Company Information
12.4.2 Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.4.3 Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.4.4 Proteo, Inc. Key Development
12.5 Prolong Pharmaceuticals
12.5.1 Prolong Pharmaceuticals Company Information
12.5.2 Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.5.3 Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.5.4 Prolong Pharmaceuticals Key Development
12.6 PledPharma AB
12.6.1 PledPharma AB Company Information
12.6.2 PledPharma AB Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.6.3 PledPharma AB Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.6.4 PledPharma AB Key Development
12.7 Pharming Group N.V.
12.7.1 Pharming Group N.V. Company Information
12.7.2 Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.7.3 Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.7.4 PledPharma AB Key Development
12.9 Opsona Therapeutics Limited
12.9.1 Opsona Therapeutics Limited Company Information
12.9.2 Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.9.3 Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.9.4 Opsona Therapeutics Limited Key Development
12.8 Orexo AB
12.8.1 Orexo AB Company Information
12.8.2 Orexo AB Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.8.3 Orexo AB Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.8.4 Orexo AB Key Development
12.11 Nyken B.V.
12.11.1 Nyken B.V. Company Information
12.11.2 Nyken B.V. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.11.3 Nyken B.V. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.11.4 Nyken B.V. Key Development
12.12 Gilead Sciences, Inc.
12.12.1 Gilead Sciences, Inc. Company Information
12.12.2 Gilead Sciences, Inc. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.12.3 Gilead Sciences, Inc. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.12.4 Gilead Sciences, Inc. Key Development
12.13 Erimos Pharmaceuticals, LLC
12.13.1 Erimos Pharmaceuticals, LLC Company Information
12.13.2 Erimos Pharmaceuticals, LLC Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.13.3 Erimos Pharmaceuticals, LLC Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.13.4 Erimos Pharmaceuticals, LLC Key Development
12.14 Ensemble Therapeutics Corporation
12.14.1 Ensemble Therapeutics Corporation Company Information
12.14.2 Ensemble Therapeutics Corporation Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.14.3 Ensemble Therapeutics Corporation Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.14.4 Ensemble Therapeutics Corporation Key Development
12.15 Curatis Pharma GmbH
12.15.1 Curatis Pharma GmbH Company Information
12.15.2 Curatis Pharma GmbH Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
12.15.3 Curatis Pharma GmbH Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
12.15.4 Curatis Pharma GmbH Key Development
12.17 Biomedica Management Corporation
12.18 Bayer AG
12.19 Antipodean Pharmaceuticals, Inc.
12.20 Angion Biomedica Corp.
12.21 Amyndas Pharmaceuticals LLC

13 Global Ischemia Reperfusion Injury Therapeutics Market Forecast by Region by Type and by Application
13.1 Global Ischemia Reperfusion Injury Therapeutics Revenue Forecast 2022-2027
13.2 Global Ischemia Reperfusion Injury Therapeutics Forecast by Regions
13.3 Global Ischemia Reperfusion Injury Therapeutics Forecast by Type
13.4 Global Ischemia Reperfusion Injury Therapeutics Forecast by Application

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer

List of Figure

List of Tables

Table 1: Global Ischemia Reperfusion Injury Therapeutics Production Specifications
Table 2: Drivers in Ischemia Reperfusion Injury Therapeutics Market
Table 3: Restraints Ischemia Reperfusion Injury Therapeutics Market
Table 4: Opportunity in Ischemia Reperfusion Injury Therapeutics Market
Table 5: Comparion of Alternative and Ischemia Reperfusion Injury Therapeutics
Table 6: Ischemia Reperfusion Injury Therapeutics Raw Materials Key Suppliers List
Table 7: Ischemia Reperfusion Injury Therapeutics Distributors List
Table 8: Ischemia Reperfusion Injury Therapeutics Major Buyers in Application One
Table 9: Ischemia Reperfusion Injury Therapeutics Major Buyers in Application Two
Table 10: Ischemia Reperfusion Injury Therapeutics Major Buyers in Application Three
Table 11: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Type 2016-2021
Table 12: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Type 2016-2021
Table 18: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Application 2016-2021
Table 19: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Application 2016-2021
Table 20: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Region 2016-2021
Table 21: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Region 2016-2021
Table 22: North America Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Country 2016-2021
Table 23: North America Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country 2016-2021)
Table 24: Europe Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Country 2016-2021
Table 25: Europe Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country 2016-2021)
Table 26: Asia Pacific Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Country 2016-2021
Table 27: Asia Pacific Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country 2016-2021)
Table 28: South America Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Country 2016-2021
Table 29: South America Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country 2016-2021)
Table 30: Middle East and Africa Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) by Country 2016-2021
Table 31: Middle East and Africa Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country 2016-2021)
Table 32 Zealand Pharma A/S Company Information
Table 33 Zealand Pharma A/S Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 34 Zealand Pharma A/S Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 35 Stealth BioTherapeutics Inc. Company Information
Table 36 Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 37 Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 38 Prothix BV Company Information
Table 39 Prothix BV Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 40 Prothix BV Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 41 Proteo, Inc. Company Information
Table 42 Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 43 Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 44 Prolong Pharmaceuticals Company Information
Table 45 Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 46 Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 47 PledPharma AB Company Information
Table 48 PledPharma AB Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 49 PledPharma AB Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 50 Pharming Group N.V. Company Information
Table 51 Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 52 Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 53 Orexo AB Company Information
Table 54 Orexo AB Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 55 Orexo AB Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 56 Opsona Therapeutics Limited Company Information
Table 57 Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Product Portfolio, Specification and Application
Table 58 Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Revenue and Gross Margin (2019-2021)
Table 59: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Forecast by Region (2022-2027)
Table 60: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share Forecast by Region (2022-2027)
Table 61: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Forecast by Type (2022-2027)
Table 62: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share Forecast by Type (2022-2027)
Table 63: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Forecast by Application (2022-2027)
Table 64: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share Forecast by Application (2022-2027)


List of Figures

Figure 1: Ischemia Reperfusion Injury Therapeutics Picture
Figure 2: Global Ischemia Reperfusion Injury Therapeutics Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Ischemia Reperfusion Injury Therapeutics Industry Life Cycle
Figure 5: Product Picture of ANV-6L15
Figure 6: Product Picture of APP-103
Figure 9: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Type, 2020
Figure 10: Ischemia Reperfusion Injury Therapeutics in Clinic
Figure 11: Global Ischemia Reperfusion Injury Therapeutics Market: Clinic 2016-2021
Figure 12: Ischemia Reperfusion Injury Therapeutics in Hospital
Figure 13: Global Ischemia Reperfusion Injury Therapeutics Market: Hospital 2016-2021
Figure 14: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Application, 2020
Figure 15: Global Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Region 2016-2021
Figure 16: North America Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 7: Europe Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 8: Asia Pacific Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 9: South America Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 10: Middle East and Africa Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 11: North America Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country, 2020
Figure 12: United States Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 13: Canada Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 14: Mexico Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 15: Europe Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country, 2020
Figure 16: Germany Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 17: France Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 18: UK Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 19: Italy Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 20: Russia Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 21: Spain Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country, 2020
Figure 23: China Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 24: Japan Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 25: Korea Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 26: Southeast Asia Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 27: India Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 28: Australia Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 29: South America Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country, 2020
Figure 30: Brazil Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 31: Argentina Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 32: Colombia Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 33: Middle East and Africa Ischemia Reperfusion Injury Therapeutics Revenue Market Share by Country, 2020
Figure 34: Turkey Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 35: Saudi Arabia Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 36: South Africa Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Status 2016-2021
Figure 37: Zealand Pharma A/S Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 38: Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 39: Prothix BV Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 40: Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 41: Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 42: PledPharma AB Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 43: Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 44: Orexo AB Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 45: Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 46: Omeros Corporation Ischemia Reperfusion Injury Therapeutics Revenue Market Share Globally (2019-2021)
Figure 47: Global Ischemia Reperfusion Injury Therapeutics Revenue (Million USD) Forecast (2022-2027)